Cantor Fitzgerald analyst Eric Schmidt initiated coverage of Avidity Biosciences with an Overweight rating and $60 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RNA:
- Dyne Therapeutics price target raised to $37 from $33 at Guggenheim
- Avidity Biosciences price target raised to $33 from $23 at Chardan
- Avidity Biosciences Reveals Promising Trial Results and Phase 3 Plans
- Avidity Biosciences announces ‘positive’ data from MARINA-OLE trial
- Avidity Biosciences Launches Major Stock and Warrants Placement
